Angiotensin-Converting Enzyme Inhibitors and Receptor Blockers Usage in COVID-19 Illness Leading to Confusion or Conclusion: a Comprehensive Review

Abstract

In the present situation, the consequence of the Angiotensin-Converting Enzyme inhibitors (ACEi) and Angiotensin Receptor Blockers (ARB) is being questioned since its usage has increased progressively due to its significance in the medical field as lifesaving drugs associated with cardiovascular diseases and renal failure. The novel study of these by researchers all around the world is showing varied opinions. Hence, the usage of the above-inhibitors in COVID-19 patients is reviewed, also discussing its pharmacological importance. This review is about the coronavirus's efficiency to develop in hosts who are in the regular treatment of ACEi and ARB. Besides, there is also a detailed mechanism of the coronavirus's attack on the host, which is reviewed. This gives a brief idea adopted for conventional approaches. It is also a detailed study of the ACEi/ARB in COVID-19 patients. It is believed this review particularly will help give a clear idea of ACEi/ARB in treating patients already suffering from the COVID-19 disease and help the further researchers in considering its use further for treating COVID-19 patients and to categorize it as a threat or not.